May 24, 2017 08:32 AM EDT
Financing
China

Ge Li’s fast-grow­ing WuXi Bi­o­log­ics sets the stage for a $513M IPO

John Carroll

Editor & Founder

WuXi Bi­o­log­ics, a big one-stop shop for drug dis­cov­ery, de­vel­op­ment and man­u­fac­tur­ing in Chi­na, has re­port­ed­ly set its sights on a $513 mil­lion IPO. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Ipsen se­cures rights to pre­clin­i­cal T cell en­gager in $610M pact with French biotech

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

A service from the Financial Times